Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ENZALUTAMIDE Cause Systemic inflammatory response syndrome? 5 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Systemic inflammatory response syndrome have been filed in association with ENZALUTAMIDE (Xtandi). This represents 0.0% of all adverse event reports for ENZALUTAMIDE.

5
Reports of Systemic inflammatory response syndrome with ENZALUTAMIDE
0.0%
of all ENZALUTAMIDE reports
1
Deaths
5
Hospitalizations

How Dangerous Is Systemic inflammatory response syndrome From ENZALUTAMIDE?

Of the 5 reports, 1 (20.0%) resulted in death, 5 (100.0%) required hospitalization.

Is Systemic inflammatory response syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does ENZALUTAMIDE Cause?

Fatigue (8,891) Death (6,680) Malignant neoplasm progression (4,696) Prostatic specific antigen increased (3,731) Asthenia (3,589) Drug ineffective (3,468) Hot flush (3,144) Decreased appetite (3,069) Nausea (2,898) Dizziness (2,776)

What Other Drugs Cause Systemic inflammatory response syndrome?

DOXORUBICIN (161) METHOTREXATE (158) CYCLOPHOSPHAMIDE (153) CYTARABINE (153) METHYLPREDNISOLONE (117) ADALIMUMAB (107) RITUXIMAB (106) PREDNISOLONE (99) VINCRISTINE (97) MYCOPHENOLATE MOFETIL (95)

Which ENZALUTAMIDE Alternatives Have Lower Systemic inflammatory response syndrome Risk?

ENZALUTAMIDE vs EPCORITAMAB ENZALUTAMIDE vs EPCORITAMAB-BYSP ENZALUTAMIDE vs EPERISONE ENZALUTAMIDE vs EPHEDRINE ENZALUTAMIDE vs EPINASTINE

Related Pages

ENZALUTAMIDE Full Profile All Systemic inflammatory response syndrome Reports All Drugs Causing Systemic inflammatory response syndrome ENZALUTAMIDE Demographics